N-acetyl cysteine attenuates acute lung injury in the rat.
The development of the adult respiratory distress syndrome (ARDS) in the critically ill patient is associated with a significant morbidity and mortality. The pulmonary dysfunction in ARDS is largely secondary to neutrophil-mediated oxidant injury. The purpose of these studies is to examine the effect of the antioxidant N-acetyl cysteine (NAC) on a rodent model of lung injury. We postulated that NAC might attenuate lung injury following intratracheal challenge with endotoxin (lipopolysaccharide; LPS). Male Sprague-Dawley rats were administered NAC systemically either before or after intratracheal administration of LPS. Lung injury was assessed by measuring the transpulmonary leakage of 125I-labeled albumin, pulmonary myeloperoxidase content, bronchoalveolar lavage fluid cell counts, pulmonary lipid peroxidation and histology. NAC administration significantly attenuated the LPS-induced increases in lung permeability (LPS: .24 +/- .08 vs. LPS + NAC: .12 +/- .03, p < .05) and reduced the LPS-dependent increase in lipid peroxidation. However, total and differential bronchoalveolar lavage cell counts and myeloperoxidase content were not affected by NAC pretreatment. Although neutrophil influx was unaffected, neutrophil activation as assessed by surface CD11b expression and chemiluminescence was significantly down-regulated by NAC. Importantly, NAC administration up to 2 h after endotoxin challenge was still able to significantly ameliorate LPS-induced lung injury. Our data suggests that the attenuation of acute lung injury by NAC in our rodent model is related to free radical scavenging and inhibition of the neutrophil oxidative burst, rather than by an effect on inflammatory cell migration. These results suggest novel approaches for therapeutic interventions in acute lung injury.
Davreux
C J
CJ
Department of Surgery, University of Toronto, Ontario, Canada.
Soric
I
I
Nathens
A B
AB
Watson
R W
RW
McGilvray
I D
ID
Suntres
Z E
ZE
Shek
P N
PN
Rotstein
O D
OD
D000111:Acetylcysteine / Q000627:therapeutic use*; D000208:Acute Disease; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D018845:CD11 Antigens / Q000097:blood / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002452:Cell Count / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000633:toxicity; D005978:Glutathione / Q000032:analysis / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D015227:Lipid Peroxidation / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000737:chemistry; D008168:Lung / Q000737:chemistry / Q000187:drug effects*; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D055370:Lung Injury; D008297:Male; D018375:Neutrophil Activation / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D009195:Peroxidase / Q000187:drug effects / Q000378:metabolism; D011654:Pulmonary Edema / Q000139:chemically induced; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism
D000975:Antioxidants; D018845:CD11 Antigens; D004731:Endotoxins; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; D005978:Glutathione; D000111:Acetylcysteine